Please login to the form below

Not currently logged in
Email:
Password:

SNG001

This page shows the latest SNG001 news and features for those working in and with pharma, biotech and healthcare.

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs. ... SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation.

Latest news

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    Clearly not deterred by this, AZ has moved on to build on its respiratory franchise by in-licensing Synairgen's inhaled beta interferon SNG001.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics